INOSR Experimental Sciences 13(2):62-66, 2024.
©INOSR PUBLICATIONS
International Network Organization for Scientific Research
https://doi.org/10.59298/INOSRES/2024/1326266.000

ISSN: 2705-1692
INOSRES1326266.00

Advances in Artemisinin Resistance: Mechanisms, Detection, and Novel Therapeutic Approaches

Namukasa Mugerwa F.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Artemisinin-based combination therapies (ACTs) have been instrumental in reducing global malaria mortality over the past two decades. However, the rise of artemisinin resistance, particularly in Southeast Asia and parts of Africa, threatened these gains. Artemisinin resistance was characterized by delayed parasite clearance and is primarily driven by mutations in the kelch13 (K13) gene, which reduce the drug's efficacy. This review explored the mechanisms behind artemisinin resistance, including genetic mutations, parasite stress responses, and reduced ring-stage sensitivity. Detection strategies, such as the use of molecular markers like K13 mutations and in vitro phenotypic assays, were discussed in detail. To combat resistance, novel therapeutic approaches were emerging, including the optimization of ACTs, the use of triple-drug regimens, host-directed therapies, and gene-editing technologies. The article highlighted the need for new antimalarial drugs, improved diagnostic tools, and global collaboration to address this growing challenge. We conducted the review by analyzing recent literature and summarizing advances in both resistance mechanisms and therapeutic strategies. Finally, future directions were outlined, emphasizing the importance of research, regulatory frameworks, and investment to mitigate the spread of resistance and ensure effective malaria control.

Keywords: Artemisinin resistance, K13 mutations, malaria treatment, combination therapies, gene editing, host-directed therapies.

INTRODUCTION

Malaria remains a global health burden, with Plasmodium falciparum being the most lethal species responsible for the majority of cases and deaths[1–3]. Artemisinin-based combination therapies (ACTs) have been the cornerstone of malaria treatment for the last two decades due to their rapid action and efficacy, significantly reducing malaria-related mortality[4]. Artemisinin, derived from the Artemisia annua plant, targets the parasite during its asexual blood stage, ensuring rapid parasite clearance. However, the emergence and spread of artemisinin resistance, particularly in Southeast Asia and increasingly in parts of Africa, pose a grave threat to the global fight against malaria. Artemisinin resistance is characterized by delayed parasite clearance and reduced efficacy of ACTs[5, 6], driven by genetic mutations in the parasite. The first significant signs of resistance were observed in the Greater Mekong Subregion, where mutations in the kelch13 (K13) gene were identified as key markers of resistance. These mutations compromise the drug's ability to eliminate the parasite, leading to longer treatment times and increasing the risk of treatment failure. As resistance continues to spread, understanding the underlying mechanisms, improving detection methods, and developing novel therapeutic strategies are critical to curbing its impact. This review provides a detailed exploration of the advances in understanding artemisinin resistance, including the molecular mechanisms behind resistance, current techniques for detecting resistant strains, and emerging therapeutic approaches[7]. We highlight the role of genetic mutations, particularly in the kelch13 gene, in facilitating resistance, as well as the importance of advanced diagnostic tools like molecular markers and phenotypic assays. Furthermore, we discuss innovative strategies, including optimizing combination therapies, introducing new drug candidates, and leveraging cutting-edge

technologies like gene editing and host-directed therapies, to counteract resistance. Finally, we address the future challenges and prospects for overcoming artemisinin resistance in the global effort to eradicate malaria.

MECHANISMS OF ARTEMISININ RESISTANCE

Kelch13 Mutations and Genetic Basis: Artemisinin resistance is largely associated with mutations in the kelch13 (K13) gene, which plays a key role in the parasite's response to oxidative stress. Mutations in this gene, such as C580Y, R539T, and Y493H, have been linked to delayed parasite clearance times, the hallmark of artemisinin resistance. These mutations alter the protein structure, reducing the parasite's susceptibility to artemisinin by modifying its ability to degrade damaged proteins, a crucial survival mechanism under drug pressure[8, 9].

Parasite Stress Response Pathways: In addition to K13 mutations, artemisinin-resistant parasites exhibit enhanced stress response pathways. Specifically, the unfolded protein response (UPR) and autophagy mechanisms allow the parasite to survive the oxidative damage induced by artemisinin. The overactivation of these pathways enables parasites to withstand the toxic environment artemisinin creates, prolonging their survival and replication in the host[10, 11].

Reduced Ring-Stage Sensitivity: Artemisinin primarily targets the ring-stage of the malaria parasite's life cycle, a stage highly sensitive to oxidative stress. In resistant parasites, this sensitivity is diminished, allowing early ring-stage parasites to persist despite artemisinin exposure. This reduced ring-stage sensitivity contributes to the slower clearance rates observed in resistant infections and complicates treatment efficacy[12, 13].

DETECTION OF ARTEMISININ RESISTANCE

Detecting artemisinin resistance is critical to managing its spread and ensuring effective malaria treatment. The primary method for identifying resistance involves monitoring delayed parasite clearance times in patients treated with artemisinin-based combination therapies (ACTs)[14]. In regions with suspected resistance, patients are assessed through clinical trials and population-based studies to measure the time required to clear parasitemia, typically using microscopy or more sensitive molecular diagnostic tools like polymerase chain reaction (PCR)[15]. The discovery of mutations in the kelch13 (K13) gene has been a major breakthrough in detecting artemisinin resistance. Specific mutations in this gene, such as C580Y, F446I, and R539T, have been validated as molecular markers for resistance, particularly in Southeast Asia. The use of K13 molecular markers allows for rapid, large-scale surveillance by detecting these mutations in blood samples. PCR and sequencing are commonly used to screen for these mutations, providing a genetic fingerprint of resistant strains. Additionally, in vitro phenotypic assays, such as the ring-stage survival assay (RSA), are utilized to test the survival rate of parasites exposed to artemisinin[16]. These assays help confirm the presence of resistant phenotypes by assessing how well parasites can withstand drug exposure during their ring stage, which is the most susceptible phase of the parasite's life cycle. Together, these detection methods clinical, molecular, and phenotypic enable early identification of artemisinin resistance, aiding in timely interventions and the development of strategies to mitigate its spread.

NOVEL THERAPEUTIC APPROACHES

Optimizing Artemisinin-Based Combination Therapies (ACTs): One strategy to combat artemisinin resistance is optimizing current ACTs by combining artemisinin derivatives with partner drugs that target different stages of the parasite's life cycle. Increased focus has been placed on finding potent partner drugs that maintain efficacy even in the presence of K13 mutations. Drugs such as ferroquine and pyronaridine are under investigation for their potential to complement artemisinin action and enhance treatment outcomes[17].

Triple-Drug Therapies: Triple-drug regimens, which incorporate two partner drugs along with an artemisinin derivative, are being explored to reduce the likelihood of resistance development. This approach increases the pharmacological pressure on the parasite, making it more difficult for resistant strains to survive. Early trials of triple-drug therapies in regions with high resistance have shown promise in reducing treatment failure rates.[18]

Host-Directed Therapies: Another innovative approach involves targeting the host rather than the parasite. Host-directed therapies (HDTs) aim to modulate the host's immune response or metabolic pathways to inhibit parasite survival. By enhancing the host's ability to control infection, HDTs offer an alternative mechanism for combating resistant strains, potentially reducing the need for direct antiparasitic interventions[19].

Gene-Editing Technologies: Recent advances in gene-editing technologies, such as CRISPR-Cas9, offer new opportunities to combat artemisinin

resistance. Researchers are exploring the possibility of using gene-editing tools to disrupt resistance-related genes in the parasite genome, reversing resistance phenotypes. While still in the experimental phase, gene-editing holds significant promise for future malaria control strategies[20, 21].

FUTURE DIRECTIONS AND CHALLENGES

Addressing artemisinin resistance requires a multifaceted approach, with a focus on developing novel therapies, enhancing detection methods, and improving global surveillance. One future direction involves the development of new antimalarial drugs and combination therapies that can circumvent resistance. Targeting different stages of the Plasmodium lifecycle, or using drugs with distinct mechanisms of action, such as endoperoxides or novel partner drugs, could reduce reliance on artemisinin and delay further resistance. Improving diagnostic tools for more rapid and accurate detection of resistance, including advanced molecular markers beyond kelch13 mutations, will enhance surveillance efforts, especially in regions where resistance is emerging. Additionally, expanding the use of in vitro phenotypic assays and incorporating artificial intelligence (AI) and machine learning into resistance prediction could revolutionize detection capabilities. Challenges include the limited financial investment in research and development for new antimalarials, as well as the logistical difficulties of implementing widespread surveillance in resource-limited settings. Additionally, there is a need for stronger regulatory frameworks to monitor and control the use of antimalarials to prevent misuse, which accelerates resistance. Finally, overcoming the biological complexity of the parasite and resistance mechanisms, including its ability to enter dormancy or evade treatment, remains a major scientific hurdle. Addressing these challenges through global collaboration, investment in new technologies, and sustained efforts in drug development will be essential to curbing the spread of artemisinin resistance and ensuring the long-term effectiveness of malaria treatments.

CONCLUSION

The emergence of artemisinin resistance represents a significant challenge in the global fight against malaria, threatening the efficacy of the cornerstone treatment for this life-threatening disease. This review has highlighted the complex mechanisms underlying artemisinin resistance, including key genetic mutations in the kelch13 (K13) gene, enhanced stress response pathways, and diminished sensitivity of the parasite's ring stage. These mechanisms complicate treatment and necessitate urgent advancements in detection and therapeutic strategies. Detection of resistance has advanced with the identification of K13 mutations and the development of molecular and phenotypic assays, yet there is a pressing need for continued improvement in diagnostic tools to keep pace with the evolving resistance landscape. Novel therapeutic approaches, such as optimizing ACTs, exploring triple-drug regimens, and investigating host-directed therapies and gene-editing technologies, offer promising avenues to counteract resistance and improve treatment outcomes. Looking forward, overcoming artemisinin resistance requires a multifaceted strategy. This includes the development of new antimalarial drugs with unique mechanisms of action, the refinement of detection methods, and the enhancement of global surveillance and regulatory frameworks. Investment in research and development, combined with international collaboration and robust regulatory measures, will be crucial in addressing the challenges posed by resistance and ensuring the long-term success of malaria control efforts. By tackling these issues comprehensively, the global health community can work towards effectively mitigating the impact of artemisinin resistance and advancing the goal of malaria eradication.

REFERENCES

1. 1. Adebayo, J.O., Tijjani, H., Adegunloye, A.P., Ishola, A.A., Balogun, E.A., Malomo, S.O.: Enhancing the antimalarial activity of artesunate. Parasitol Res. 119, 2749–2764 (2020). https://doi.org/10.1007/s00436-020-06786-1
2. Akide Ndunge, O.B., Kilian, N., Salman, M.M.: Cerebral Malaria and Neuronal Implications of *Plasmodium Falciparum* Infection: From Mechanisms to Advanced Models. Advanced Science. 9, 2202944 (2022). https://doi.org/10.1002/advs.202202944
3. Alum, E., Ugwu, P.-C., Egba, S., Uti, D., Alum, B., Extension, K.P.: Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. INOSR Scientific Research. 11, 16–22 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.21622

4. K, T., Rj, C.: Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning? The Lancet. Infectious diseases. 23, (2023). https://doi.org/10.1016/S1473-3099(23)00265-7
5. Kokori, E., Olatunji, G., Akinboade, A., Akinoso, A., Egbunu, E., Aremu, S.A., Okafor, C.E., Oluwole, O., Aderinto, N.: Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts. Malaria Journal. 23, 25 (2024). https://doi.org/10.1186/s12936-024-04844-y
6. Thriemer, K., Commons, R.J.: Tafenoquine and artemisinin-based combination therapy for vivax malaria: end of the road or just the beginning? The Lancet Infectious Diseases. 23, 1100–1102(2023). https://doi.org/10.1016/S1473-3099(23)00265-7
7. van der Pluijm, R.W., Amaratunga, C., Dhorda, M., Dondorp, A.M.: Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm? Trends in Parasitology. 37, 15–24 (2021). https://doi.org/10.1016/j.pt.2020.09.011
8. Ward, K.E., Fidock, D.A., Bridgford, J.L.: Plasmodium falciparum resistance to artemisinin-based combination therapies. Curr Opin Microbiol. 69, 102193 (2022). https://doi.org/10.1016/j.mib.2022.102193
9. Talman, A.M., Clain, J., Duval, R., Ménard, R., Ariey, F.: Artemisinin Bioactivity and Resistance in Malaria Parasites. Trends in Parasitology. 35, 953–963 (2019). https://doi.org/10.1016/j.pt.2019.09.005
10. Ray, A., Mathur, M., Choubey, D., Karmodiya, K., Surolia, N.: Autophagy Underlies the Proteostasis Mechanisms of Artemisinin Resistance in P. falciparum Malaria. mBio. 13, e00630-22 (2022). https://doi.org/10.1128/mbio.00630-22
11. Rocamora, F., Zhu, L., Liong, K.Y., Dondorp, A., Miotto, O., Mok, S., Bozdech, Z.: Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites. PLoS Pathog. 14, e1006930 (2018). https://doi.org/10.1371/journal.ppat.1006930
12. Witkowski, B., Khim, N., Chim, P., Kim, S., Ke, S., Kloeung, N., Chy, S., Duong, S., Leang, R., Ringwald, P., Dondorp, A.M., Tripura, R., Benoit-Vical, F., Berry, A., Gorgette, O., Ariey, F., Barale, J.-C., Mercereau-Puijalon, O., Menard, D.: Reduced Artemisinin Susceptibility of Plasmodium falciparum Ring Stages in Western Cambodia. Antimicrob Agents Chemother. 57, 914–923 (2013). https://doi.org/10.1128/AAC.01868-12
13. Egwu, C.O., Pério, P., Augereau, J.-M., Tsamesidis, I., Benoit-Vical, F., Reybier, K.: Resistance to artemisinin in falciparum malaria parasites: A redox-mediated phenomenon. Free Radic Biol Med. 179, 317–327 (2022). https://doi.org/10.1016/j.freeradbiomed.2021.08.016
14. Mohon, A.N., Menard, D., Alam, M.S., Perera, K., Pillai, D.R.: A Novel Single-Nucleotide Polymorphism Loop Mediated Isothermal Amplification Assay for Detection of Artemisinin-Resistant Plasmodium falciparum Malaria. Open Forum Infectious Diseases. 5, ofy011(2018). https://doi.org/10.1093/ofid/ofy011
15. Sanmoung, W., Sawangjaroen, N., Jitueakul, S., Buncherd, H., Tun, A.W., Thanapongpichat, S., Imwong, M.: Application of loop-mediated isothermal amplification combined with lateral flow assay visualization of Plasmodium falciparum kelch 13 C580Y mutation for artemisinin resistance detection in clinical samples. Acta Tropica. 246, 106998 (2023). https://doi.org/10.1016/j.actatropica.2023.106998
16. Noreen, N., Ullah, A., Salman, S.M., Mabkhot, Y., Alsayari, A., Badshah, S.L.: New insights into the spread of resistance to artemisinin and its analogues. Journal of Global Antimicrobial Resistance. 27, 142–149 (2021). https://doi.org/10.1016/j.jgar.2021.09.001
17. Erhunse, N., Sahal, D.: Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures. Journal of Pharmaceutical Analysis. 11, 541–554 (2021). https://doi.org/10.1016/j.jpha.2020.07.005
18. Ansbro, M.R., Itkin, Z., Chen, L., Zahoranszky-Kohalmi, G., Amaratunga, C., Miotto, O., Peryea, T., Hobbs, C.V., Suon, S., Sá, J.M., Dondorp, A.M., van der Pluijm, R.W., Wellems, T.E., Simeonov, A., Eastman, R.T.: Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Plasmodium falciparum Genotype. ACS Pharmacol Transl Sci. 3, 1144–1157 (2020). https://doi.org/10.1021/acsptsci.0c00110
19. Matteucci, K.C., Correa, A.A.S., Costa, D.L.: Recent Advances in Host-Directed Therapies

for Tuberculosis and Malaria. Front Cell Infect Microbiol. 12, 905278 (2022). https://doi.org/10.3389/fcimb.2022.905278

20. Nourani, L., Mehrizi, A.A., Pirahmadi, S., Pourhashem, Z., Asadollahi, E., Jahangiri, B.: CRISPR/Cas advancements for genome editing, diagnosis, therapeutics, and vaccine development for *Plasmodium* parasites, and genetic engineering of *Anopheles* mosquito vector. Infection, Genetics and Evolution. 109, 105419(2023). https://doi.org/10.1016/j.meegid.2023.105419
21. Ishizaki, T., Hernandez, S., Paoletta, M.S., Sanderson, T., Bushell, E.S.C.: CRISPR/Cas9 and genetic screens in malaria parasites: small genomes, big impact. Biochem Soc Trans. 50, 1069–1079(2022). https://doi.org/10.1042/BST20210281

CITE AS: Namukasa Mugerwa F. (2024). Advances in Artemisinin Resistance: Mechanisms, Detection, and Novel Therapeutic Approaches. INOSR Experimental Sciences 13(2):62-66. https://doi.org/10.59298/INOSRES/2024/1326266.000